General Proximity
-68%
est. 2Y upside i
The next generation of induced-proximity medicines.
Rank
#75
Sector
Biotechnology
Est. Liquidity
~8Y
Data Quality
Data: MediumThis opportunity presents a compelling, albeit high-risk, equity upside driven by a validated, novel platform in the rapidly expanding field of induced proximity medicines, underscored by a significant partnership with Daiichi Sankyo.
Last updated: February 16, 2026
The OmniTAC platform achieves early clinical success in multiple programs and secures additional lucrative partnerships or a significant Series A/B funding round, leading to a substantial valuation increase.
The company successfully advances its lead programs into preclinical or early clinical stages, validates its platform through the Daiichi Sankyo collaboration, and secures a follow-on funding round at a higher valuation.
Preclinical development faces significant challenges, the Daiichi Sankyo collaboration yields limited results, or the company struggles to secure sufficient follow-on funding in a competitive biotech landscape, leading to a substantial loss in valuation or potential failure.
Other — 8 roles
- Director/Vice President, Drug Discovery & Development · San Francisco, CA
- Lab Technician/Operations Manager (Contract) · San Francisco, CA
- Other Positions · San Francisco, CA
- +5 more →
Last updated: March 10, 2026
Community
Valuation Sentiment
Our model estimates -68% upside. What do you think?
Anonymous. Do not share material non-public information.
Community Discussion
Comments are reviewed before they appear publicly.
Loading comments...
Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.